Analyst Report: LMT
1. EXECUTIVE SUMMARY
Lockheed Martin rose 14.19% over the week to a $629.75 close on October 28, 2026, from $551.51 on October 21. Three events account for most of the gain: a third-quarter beat with raised guidance on October 22 (+6.96%), a cluster of analyst target increases on October 23 (+2.42%), and a Morgan Stanley upgrade to Overweight on October 26 (+5.13%). The same-day announcement of a 10-year F-35 framework, which the brief describes as dependent on congressional authority and not yet a signed contract, supplied the common thread. The stock outperformed most defense peers while the S&P 500 fell 0.17% over the period. The shares now trade above both the 50-day and 200-day averages, and the remaining question is whether Congress grants the multiyear F-35 authority the framework requires.
2. THE CATALYST
October 22 (+6.96%, volume 2,957,700). Lockheed Martin's 8-K, released before the open, reported third-quarter sales up 11% to $20.7B and EPS of $7.97, which beat consensus. Record backlog reached $292.0B, including $52.5B tied to a PAC-3 MSE interceptor award. Investing.com reported that the company raised full-year guidance for the second consecutive quarter.
On the same day, the Department of War and Lockheed announced a 10-year F-35 framework covering at least 850 U.S. jets at 156 a year (Credence Research and GlobalMilitary). It depends on Congress granting multiyear authority and appropriations, so it is not a signed contract. Lockheed's release described it as fixed-price with cash-flow neutrality during the investment period (24/7 Wall St.).
October 23 (+2.42%). TipRanks and CNN listed target increases from UBS ($692 from $653), Citi ($706 from $691), RBC ($600 from $550, Sector Perform), BNP Paribas ($670 from $560) and Barclays ($560 from $554).
October 26 (+5.13%, volume 2,666,700). Morgan Stanley's Kristine Liwag upgraded the stock to Overweight from Equal-weight and raised the target to $835 from $690, citing removal of the risk that F-35 volumes are cut to fund missiles (24/7 Wall St.). TipRanks lists the upgrade a day earlier, on October 25, a Sunday, but 24/7 Wall St. and MarketScreener date it October 26, which is the session that moved.
October 27 (-1.92%) and October 28 (+1.09%). The research found no company-specific catalyst for either session. A $694M ARRW hypersonic contract announced on October 27 is too small to explain that day's decline (Yahoo/PRNewswire). The two articles dated October 28 were published after the close, so they cannot explain that session.
| Date | Close | Change | Driver |
|---|---|---|---|
| Oct 21 | $551.51 | +0.51% | None identified |
| Oct 22 | $589.91 | +6.96% | Q3 beat, guidance raise, F-35 framework |
| Oct 23 | $604.18 | +2.42% | Target raises |
| Oct 26 | $635.20 | +5.13% | Morgan Stanley upgrade |
| Oct 27 | $622.99 | -1.92% | No catalyst found |
| Oct 28 | $629.75 | +1.09% | No sourced catalyst |
3. COMPANY PROFILE
Lockheed Martin is an aerospace and defense company in the Industrials sector with four segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems, and Space. Its market cap is $145.48bn. Competitors in the facts panel include Northrop Grumman and RTX, with Boeing and GE Aerospace also in the group.
Revised 2026 guidance, per the company release, puts sales at $80–82B (from $79.75–81.75B), EPS at about $30.35–30.75 (from $29.95–30.65) and operating cash flow at about $10.0–10.2B. MFC drove the raise, with sales and profit both up 24% year over year on munitions production ramps (Benzinga transcript). Aeronautics sales rose 13% on F-35 production and sustainment (Yahoo Finance). Quartz reported that Lot 20 F-35 advance acquisition costs began exceeding contractual authorization and funding in the quarter. Management said Lot 20 is not in 2026 guidance and that the framework includes recovery provisions if volumes are later cut (24/7 Wall St.).
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The earnings beat and the second consecutive guidance raise support a re-rating on their own. The guidance midpoint moved only modestly, however: the sales range rose by $250M at the midpoint. A gain of 14.19% in a week therefore rests heavily on the F-35 framework and the sentiment shift that followed. This is inference, but the sequence of daily moves supports it, since the largest gains on October 22 and October 26 coincided with the framework news and the F-35-focused upgrade.
Peer read-across. Over the same period, Northrop Grumman rose 2.50%, RTX 2.21%, GE 1.77% and Honeywell 8.97%, while Boeing fell 13.07% and Howmet 6.23%. Morgan Stanley's rationale is specific to LMT, since the F-35 is 20–30% of its revenue (24/7 Wall St.), which fits the gap to the closest defense peers. Boeing's decline stemmed from its own production-rate and delivery problems (Motley Fool, headline only) and is not a sector signal.
Comparable episode. Lockheed also raised its full-year outlook on Q3 2024 results on October 22, 2024, with backlog above $165B (8-K). A third-quarter beat and raise has recurred, though the 2024 stock reaction is not in the brief.
Bull case. Backlog of $292.0B gives multi-year visibility, munitions demand is lifting MFC, and the framework removes the F-35 cut overhang. Morgan Stanley's $835 target sits well above the $645 consensus (24/7 Wall St. and Defense World, across 23 analysts: 1 Strong Buy, 10 Buy, 10 Hold, 1 Sell).
Bear case. The close of $629.75 sits just below the roughly $645 consensus target, so the average analyst sees limited upside. Several recent raises landed below the share price: Barclays at $560, RBC at $600, Jefferies at $615 and Bank of America at $620. Congress has not granted the authority the framework needs, and the Lot 20 funding issue is unresolved. Forward P/E of 19.0 compares with trailing 22.1.
5. TECHNICAL SNAPSHOT
The close of $629.75 sits well above the 50-day average of $541.08 and the 200-day average of $562.51, and the stock has gained 23.66% in 20 sessions. It remains below the 52-week high of $683.27 set on March 2, and far above the 52-week low of $429.47. The nearest resistance is the October 26 close of $635.20. The nearest support is the October 27 close of $622.99, with the October 23 close of $604.18 below it. Volume of 1,662,900 on the latest session was 1.32x the 50-session average, and volume on October 22 and October 26 ran at more than twice that average, which confirms heavy participation in the move.
6. RISK FACTORS
- Congress has not granted multiyear F-35 authority, and a formal contract and pricing can only follow that decision (Credence Research). Lockheed says terms would be finalized "in the coming months" afterward (GlobalMilitary).
- Lot 20 costs exceeding authorization remain open (Quartz).
- Management describes the framework as fixed-price, which places cost overrun risk on the company.
- The stock has risen 23.66% in 20 sessions, which leaves it exposed to profit-taking. A headline from October 20 referenced defense stocks falling on bets for a Democratic sweep (24/7 Wall St., headline only), so political risk to budgets is present.
- The brief did not source the next earnings date, so check the company's investor relations calendar.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks). The shares sit between support at $622.99 and resistance at $635.20. With no sourced catalyst for the last two sessions, price action is likely to depend on further analyst revisions and defense budget headlines. Consolidation near current levels is the base case (inference).
Medium term (1-3 months). The key event is congressional action on multiyear F-35 authority. Authority granted would validate the framework and the Morgan Stanley thesis, with the $683.27 high as the reference point. Delay or a funding dispute would test the $604.18 level and possibly the 50-day average at $541.08.
Long term. The thesis of record backlog, munitions growth and a longer F-35 runway has strengthened, while the contract terms remain unsigned and execution on a fixed-price basis is unproven. This is analysis, not personal financial advice.